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Phe Role of Platelet-Derived Growth
actor Signaling in Healing Myocardial Infarcts
awel Zymek, MD,* Marcin Bujak, MD,* Khaled Chatila, MD,* Anna Cieslak, MS,*
eeta Thakker, PHD,† Mark L. Entman, MD, FACC,* Nikolaos G. Frangogiannis, MD, FACC*
ouston, Texas
OBJECTIVES This study sought to examine the role of platelet-derived growth factor (PDGF) signaling in
healing myocardial infarcts.
BACKGROUND Platelet-derived growth factor isoforms exert potent fibrogenic effects through interactions
with PDGF receptor (PDGFR)- and PDGFR-. In addition, PDGFR- signaling
mediates coating of developing vessels with mural cells, leading to the formation of a mature
vasculature. We hypothesized that PDGFR activation may regulate fibrosis and vascular
maturation in healing myocardial infarcts.
METHODS Mice undergoing reperfused infarction protocols were injected daily with a neutralizing
anti–PDGFR- antibody (APB5), an anti-PDGFR- antibody (APA5), or control immu-
noglobulin G, and were killed after 7 days of reperfusion.
RESULTS The PDGF-B, PDGFR-, and PDGFR- mRNA expression was induced in reperfused
mouse infarcts. Perivascular cells expressing phosphorylated PDGFR- were identified in the
infarct after 7 days of reperfusion, indicating activation of the PDGF-BB/PDGFR-
pathway. The PDGFR- blockade resulted in impaired maturation of the infarct vasculature,
enhanced capillary density, and formation of dilated uncoated vessels. Defective vascular
maturation in antibody-treated mice was associated with increased and prolonged extravasa-
tion of red blood cells and monocyte/macrophages, suggesting increased permeability. These
defects resulted in decreased collagen content in the healing infarct. In contrast, PDGFR-
inhibition did not affect vascular maturation, but significantly decreased collagen deposition
in the infarct.
CONCLUSIONS Platelet-derived growth factor signaling critically regulates postinfarction repair. Both
PDGFR-– and PDGFR-–mediated pathways promote collagen deposition in the infarct.
Activation of PDGF-B/PDGFR- is also involved in recruitment of mural cells by
neovessels, regulating maturation of the infarct vasculature. Acquisition of a mural coat and
maturation of the vasculature promotes resolution of inflammation and stabilization of the
scar. (J Am Coll Cardiol 2006;48:2315–23) © 2006 by the American College of Cardiology
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.07.060Foundation
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onfarct healing is regulated by a well-orchestrated inflam-
atory response that ultimately leads to formation of a scar
1,2). Myocardial necrosis results in marked induction of
nflammatory mediators and recruitment of leukocytes in
he infarcted myocardium. Activated neutrophils and
ononuclear cells secrete proteolytic enzymes and debride
he infarcted area from dead cells and extracellular matrix
ragments. The inflammatory phase is followed by the
roliferative phase of healing, when fibroblasts accumulate
n the infarct granulation tissue and deposit extracellular
atrix proteins (3). During the proliferative phase the
ound is highly cellular and metabolically active and re-
uires a rich vascular supply to provide the proliferating cells
ith oxygen and nutrients. Thus, formation of infarct
eovessels is a critical part of the healing process. As the
ound matures, resolution of the inflammatory infiltrate
ccurs and the highly vascular granulation tissue is replaced
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ccepted July 17, 2006.y collagen-rich scar. The infarct vasculature undergoes
ynamic changes: infarct angiogenesis is suppressed, and
any infarct neovessels acquire a muscular coat (4,5) while
ncoated vessels regress. As a result, the mature scar
ontains few capillaries and a large number of coated
rterioles (5). Resolution of the inflammatory response and
aturation of the neovasculature may be important steps in
nfarct healing, necessary to prevent uncontrolled angiogen-
sis and expansion of granulation tissue formation.
Platelet-derived growth factor (PDGF) signaling regu-
ates events critical to fibrous tissue deposition and angio-
enesis through interactions with its 2 PDGF receptors
PDGFR)  and . Activation of both PDGFR- and
DGFR- pathways stimulates fibroblast migration, pro-
iferation, and activation (6–8). In addition, PDGF-BB/
DGFR- interactions play a crucial role for investment of
eveloping vessels with pericytes, a key process in vascular
aturation (9,10). Endothelial cells form vascular tubes and
irect the recruitment of mural cell precursors by secreting
DGF-BB (11), whereas PDGFR- is expressed by peri-
ytes and smooth muscle cells. Although the critical signif-
cance of PDGFR-–mediated pericyte coating in embry-
nic vascular development has been established (12,13), the
mportance of vascular maturation and acquisition of a
m
I
m
s
h
t
n
m
i
r
m
a
n
m
f
p
v
s
t
o
d
m
i
r
M
M
t
I
t
m
t
t
c
t
c
T
f
t
i
i
a
i
r
a
u
a
I
t
w
(
m
I
(
P
v
i
u
E
n
o
k
F
a
A
C
Q
d
p
i
d
d
s
a
t
u
v
v
p
p
a
P
n
(
R
c
f
r
R
c
f
s
r
p
u
P
f
w
2316 Zymek et al. JACC Vol. 48, No. 11, 2006
PDGF Signaling in Myocardial Infarction December 5, 2006:2315–23uscular coat in healing wounds has not been investigated.
n the retina, investment of the vessels with mural cells
arks the end of the plasticity window and leads to vascular
tabilization (14) and decreased angiogenic potential. We
ypothesized that activation of the PDGFR- pathway in
he infarcted myocardium is crucial for maturation of infarct
eovessels and acquisition of a muscular coat. Thus, recruit-
ent of mural cells by infarct neovessels may be important
n mediating suppression of the angiogenic process and
esolution of the inflammatory infiltrate during wound
aturation.
Our study examined the effects of disrupted PDGFR-
nd PDGFR- signaling, through systemic injection of
eutralizing antibodies (15), on infarct angiogenesis, wound
aturation, and scar formation in reperfused murine in-
arcts. The PDGFR- inhibition resulted in impaired
ericyte coating, formation of a chaotic and tortuous infarct
asculature, increased capillary density, prolonged extrava-
ation of blood cells, and impaired collagen deposition in
he infarct. In contrast, PDGFR- inhibition had no effect
n vascular maturation but significantly attenuated collagen
eposition in the infarcted myocardium. Acquisition of a
uscular coat through PDGF-BB/PDGFR- interactions
s critical for stabilization of the infarct neovessels and
esolution of the postinfarction inflammatory response.
ETHODS
urine ischemia/reperfusion protocols. All animal pro-
ocols were approved by the Baylor College of Medicine
nstitutional Review Board. Wild-type C57/BL/6 mice, 8
o 12 weeks of age (purchased from Charles River, Wil-
ington, Massachusetts), were used for myocardial infarc-
ion experiments. Mice were anesthetized by an intraperi-
oneal injection of sodium pentobarbital (10 g/g). A
losed-chest mouse model of reperfused myocardial infarc-
ion was used as previously described (16,17) to avoid the
onfounding effects of surgical trauma and inflammation.
he left anterior descending coronary artery was occluded
or 1 h and then reperfused for 6 h to 7 days. At the end of
he experiment, the chest was opened and the heart was
mmediately excised, fixed in zinc formalin, and embedded
n paraffin for histological studies, or snap frozen and stored
t 80°C for RNA isolation. Sham animals were prepared
dentically without undergoing coronary occlusion/
Abbreviations and Acronyms
APA  anti–PDGFR- antibody
APB  anti–PDGFR- antibody
IgG  immunoglobulin G
PCR  polymerase chain reaction
PDGF  platelet-derived growth factor
PDGFR  platelet-derived growth factor receptor
SMA  smooth muscle actineperfusion. Animals used for histology underwent 72-h ind 7-day reperfusion protocols (5 animals per group). Mice
sed for RNA extraction underwent 6 h, 24 h, 48 h, 72 h,
nd 7 days of reperfusion (3 animals per group).
mmunohistochemistry and quantitative histology. Sec-
ions were cut at 3 m and stained immunohistochemically
ith the following antibodies: anti- smooth muscle actin
-SMA) (Sigma, St. Louis, Missouri), rat anti-mouse
acrophage antibody clone F4/80 (Research Diagnostics
nc., Flanders New Jersey), rat anti-neutrophil antibody
Serotec, Raleigh, North Carolina), anti-phosphorylated
DGFR- antibody (Upstate Biotechnology, Charlottes-
ille, Virginia), and rat anti-mouse CD31 antibody (Pharm-
ngen, San Diego, California). Staining was performed
sing a peroxidase-based technique with the Vectastain
LITE rat or goat kit (Vector Labs, Burlingame, Califor-
ia). Negative control procedures were performed with
mission of the primary antibodies. The Mouse-on-Mouse
it (Vector) was used for -SMA immunohistochemistry.
or CD31 staining, sections were pretreated with trypsin
nd staining was performed using the Tyramide Signal
mplification kit (Perkin Elmer, Boston, Massachusetts).
ollagen staining was performed using picrosirius red.
uantitative assessment of macrophage and neutrophil
ensity was performed by counting the number of F4/80
ositive cells and immunoreactive neutrophils respectively
n the infarcted area (18). Macrophage and neutrophil
ensity was expressed in cells/mm2. Infarct microvascular
ensity was assessed by counting the number of CD31-
tained vascular profiles in infarcted murine hearts. To
ssess the acquisition of a muscular coat by infarct vessels,
he density of coated vessels in the infarct was measured by
sing a section stained for -SMA. The density of uncoated
essels was assessed by subtracting the density of coated
essels from the total vascular density in the infarct. The
ercentage of the infarcted area stained for collagen with
icrosirius red (collagen percent staining) was quantitatively
ssessed in infarcts after 7 days of reperfusion using Image
ro software (Image Pro Plus, version 4.5, Media Cyber-
etics Inc., Silver Spring, Maryland) as previously described
19).
NA extraction and quantitative real-time polymerase
hain reaction (PCR). Total RNA was extracted from
rozen hearts using a commercially available acid-phenol
eagent (TRIzol, Invitrogen, Carlsbad, California). Total
NA was treated with DNase to remove any genomic
ontamination as described by the manufacturer (DNA-
ree, Ambion, Austin, Texas). First-strand cDNA was
ynthesized using SuperScript II reverse transcriptase and
andom hexamer primers as described in the manufacturer’s
rotocol (Invitrogen). Relative standard curve method was
sed to measure the expression levels of PDGF-BB, -AA,
DGFR-, and PDGFR-. TaqMan primers and probes
or PDGF-BB, PDGF-AA, PDGFR-, and PDGFR-
ere obtained from Applied Biosystems (Foster City, Cal-fornia). Real-time PCR was performed and analyzed with
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December 5, 2006:2315–23 PDGF Signaling in Myocardial Infarction:10 diluted cDNA according to the manufacturer’s instruc-
ions on an ABI Prism 7000 Sequence Detection System.
arget gene expression was normalized to an internal
igure 1. The microvascular network in reperfused mouse infarcts is identi
he myocardial vasculature. (B) Serial section with omission of the prima
ranulation tissue contains many CD31-positive endothelial cells (arrowhe
apillaries (arrows) and a significant number of coated vessels (arrowhead
igure 2. The -smooth muscle actin (SMA) immunohistochemistry in
dentifies the vascular media (arrowheads). (B) Serial section stained with
f reperfusion, -SMA immunohistochemistry is predominantly localized in
arrowheads). (D) After 7 days of reperfusion, the infarct vasculature matures t
ounterstained with eosin (magnification 200).ontrol, ribosomal protein S3 (RPS3). The RPS3 was
easured using SYBR Green chemistry and the relative
tandard curve method. At the end of the PCR cycle,
y CD31 immunohistochemistry. (A) CD31 staining of control heart labels
ibody serves as a negative control. (C) After 72 h of reperfusion, infarct
(D) After 7 days of reperfusion, the infarcted area contains relatively few
ounterstained with eosin (magnification 200).
rfused murine infarcts. (A) In control murine hearts, -SMA staining
sion of the primary antibody serves as a negative control. (C) After 72 h
dle-shaped myofibroblasts (arrows). Relatively few coated vessels are notedfied b
ry antrepe
omis
spinhrough the recruitment of mural cells by infarct neovessels (arrowheads).
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PDGF Signaling in Myocardial Infarction December 5, 2006:2315–23issociation curve analysis was performed to ascertain the
mplification of a single PCR product. Sequence of the
urine primers is as follows: RPS3 forward (5=-
TCAGAGAGTTGACCGCAGTTG-3=), RPS3 re-
erse (5=-AATGAACCGAAGCACACCATAG-3=).
DGFR- and PDGFR- inhibition in mouse in-
arcts. To examine the effects of PDGFR- inhibition on
yocardial infarct healing, mice undergoing coronary oc-
lusion/reperfusion received daily intraperitoneal injections
200 g/day, the first dose was administered after 24 h of
eperfusion) with the neutralizing rat anti-mouse PDGFR-
ntibody (APB) 5, the rat anti-mouse PDGFR- antibody
igure 3. Assessment of mRNA expression of platelet-derived growth fac
B), PDGFR- (C), and PDGF-B chain (D) in mouse infarcts using q
xpression in the heart peaked after 6 h of reperfusion (**p  0.01 vs. sham
owever, the difference with sham hearts did not reach statistical significan
how a similar time course, peaking after 7 days of reperfusion (*p  0.05
igure 4. Activation of the platelet-derived growth factor receptor (PDGFR
mmunohistochemical staining with an antibody to phosphorylated PDG
PDGFR-. (B) After 7 days of reperfusion, perivascular and mononucle
ound in the infarcted myocardium. (C) Negative control with omission of
magnification 200).APA) 5 (both from eBioscience, San Diego, California), or rat
mmunoglobulin G (IgG) (Sigma) (APA5, n 7; APB5, n
; rat IgG, n  14). Selection of the dose was based on
reviously published studies using these antibodies in vivo to
nhibit PDGFR signaling in mouse models (15,20,21). After 7
ays of reperfusion the animals were killed, and the hearts were
xed in zinc formalin (Z-fix; Anatech, Battle Creek, Michi-
an) and embedded in paraffin for histological studies.
tatistical analysis. Statistical analysis was performed using
-way ANOVA followed by t test corrected for multiple
omparisons (Student-Newman-Keuls). Data were expressed
s mean values SEM. Statistical significance was set at 0.05.
ceptor (PDGFR)- (A), platelet-derived growth factor (PDGF)-A chain
tative real-time polymerase chain reaction. (A) The PDGFR- mRNA
) The PDGF-A mRNA expression also increased after 6 h of reperfusion;
 0.08). (C and D) The PDGFR- (C) and PDGF-B (D) mRNA levels
ham, **p  0.01 vs. sham).
ignaling pathway in healing murine myocardial infarcts was detected using
 (pPDGFR-). (A) Noninfarcted areas showed minimal staining for
e cells (arrowheads) with intense immunoreactivity to pPDGFR- weretor re
uanti
). (B)- s
FR-
ar-lik
the primary antibody shows no staining. Counterstained with eosin
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December 5, 2006:2315–23 PDGF Signaling in Myocardial InfarctionESULTS
ascular maturation in healing mouse infarcts. CD31
mmunohistochemistry identified the vascular network of
he mouse heart, specifically labeling endothelial cells (Figs.
A and 1B), whereas -SMA immunoreactivity was local-
zed in smooth muscle cells (Figs. 2A and 2B). After 72 h
f reperfusion, dead cardiomyocytes in the infarcted area
ere replaced with granulation tissue that contained an
xtensive capillary network (Fig. 1C). At the same time
oint, -SMA immunohistochemistry labeled a large num-
er of myofibroblasts and occasional vessels coated with
mooth muscle cells (Fig. 2C). As the wound matured,
ore infarct vessels acquired a muscular coat, and after 7
ays of reperfusion (Fig. 1D) the scar contained a significant
umber of mature, coated neovessels (Fig. 2D). Acquisition
f a muscular coat confers stability and indicates maturation
f the vasculature.
xpression of PDGF-A, PDGFR-, PDGF-B, and
DGFR- in healing infarcts. The PDGFR- mRNA
xpression was markedly induced in the infarcted myocar-
ium after 6 h of reperfusion (p  0.01, corrected for
ultiple comparisons) and decreased after 24 h of reperfu-
ion (Fig. 3A). Although PDGF-A mRNA expression also
eaked after 6 h of reperfusion, the difference between
DGF-A mRNA expression in infarcted and sham animals
as not statistically significant (Fig. 3B). In contrast,
igure 5. (A) Platelet-derived growth factor receptor (PDGFR)- and PD
A) After 7 days of reperfusion, Sirius red staining identified a well-organ
at immunoglobulin (Ig)G. (B) Mice treated with anti–PDGFR- antibod
ice injected with anti–PDGFR- antibody (APB5) showed decreased and
D) Quantitative assessment of collagen deposition in the infarcted heartDGFR- and PDGF-B mRNA showed late up- Pegulation, peaking after 7 days of reperfusion (Figs. 3C and
D).
hosphorylated PDGFR- localization in the infarcted
eart. Many perivascular cells in the healing infarct showed
xpression of phosphorylated PDGFR-, suggesting acti-
ation of the PDGF-B/PDGFR- signaling pathway (Fig
B). In contrast, minimal phosphorylated PDGFR- im-
unoreactivity was noted in the noninfarcted heart (Fig.
A).
DGFR- and PDGFR- neutralization inhibit colla-
en deposition in the healing infarct. After 7 days of
eperfusion, mouse infarcts showed replacement of the dead
ardiomyocytes with collagen-based scar. Healing infarcts
n antibody-treated animals showed decreased matrix dep-
sition in the infarcted myocardium (Fig. 5). The
DGFR- neutralization resulted in significantly dimin-
shed collagen content in the infarcted area (anti–
DGFR-: 12.45 0.48, n 7; vs. rat IgG: 20.34 1.94,
 14; p  0.05, corrected for multiple comparisons). The
DGFR- inhibition also attenuated collagen deposition in
he infarcted area (anti–PDGFR-: 13.46  1.88, n  7;
s. rat IgG: 20.34  1.94, n  14, p  0.05, corrected for
ultiple comparisons).
DGFR- but not PDGFR- neutralization results in
mpaired maturation of the infarct vasculature. The
DGFR- inhibition impaired vascular maturation and
ncreased microvascular density in healing infarcts (anti–
- inhibition decreased collagen deposition in the infarcted myocardium.
ollagen network in the infarcted heart from animals treated with control
A5) had attenuated collagen deposition in the infarcted myocardium. (C)
rganized collagen deposition. Note the presence of dilated vessels (arrows).
0.05 vs. IgG control group). Magnification 400.GFR
ized c
y (APDGFR-: 471.6  73.8 vessels/mm2 vs. IgG: 267.7 
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PDGF Signaling in Myocardial Infarction December 5, 2006:2315–233.98 vessels/mm2, p  0.01, corrected for multiple
omparisons). Anti–PDGFR- treatment resulted in
ormation of a disorganized, “chaotic” vasculature com-
rised of irregular uncoated vessels (Figs. 6C to 6F). The
DGFR- antibody-treated mice had a significantly
ower density of coated vessels (anti–PDGFR-: 70.02 
.75 vessels/mm2 vs. IgG: 117.5  15.7 vessels/mm2,
 0.05, corrected for multiple comparisons) and a
igher number of uncoated vessels compared with IgG-
njected animals (anti–PDGFR-: 401.61  68.94 ves-
els/mm2 vs. IgG: 150.16  21.83 vessels/mm2, p 
.01, corrected for multiple comparisons). In contrast,
DGFR- inhibition did not affect microvessel forma-
ion in the healing infarct (anti–PDGFR-: 216.77 
5.2 vessels/mm2, p  NS, corrected for multiple com-
igure 6. Platelet-derived growth factor receptor (PDGFR)- inhibitio
he healing infarct. (A) CD31 immunohistochemistry identified the infa
B) Numerous coated vessels were noted in the infarct after 7 days of rep
ntibody APB5 resulted in impaired vascular maturation and in format
C, magnification 200; D to F, magnification 400). (G to I) Quanti
H), and density of coated vessels (I) in the infarct. The PDGFR-
gG-treated animals) (G) and the number of uncoated vessels (**p  0
I) in the infarcted area (*p  0.05 vs. IgG-treated mice). In contrast, P
s in Figure 5.arisons) (Fig. 6). Pffects of PDGFR- and PDGFR- inhibition on
eukocyte infiltration in the healing infarct. We have
reviously shown that reperfused mouse infarcts show an
ntense but transient inflammatory reaction leading to
ormation of a mature scar after 7 to 14 days of reperfusion
17). After 7 days of reperfusion, murine myocardial scars
ontained large amounts of matrix (Fig. 4A) and relatively
ow numbers of leukocytes. The PDGFR- inhibition
esulted in prolonged extravasation of blood cells in the
ealing infarct. After 7 days of reperfusion, anti-PDGFR-
–treated mice, but not IgG-injected control mice, showed
emorrhagic areas containing extravasated red blood cells
Figs. 7A and 7B). In addition, PDGFR- neutralization
esulted in increased macrophage density in the infarcted
rea compared with IgG-treated animals (Fig. 7D). The
lted in impaired vascular maturation and enhanced capillary density in
asculature in immunoglobulin IgG-treated mice (magnification 200).
ion (arrows). (C to F) The PDGFR- inhibition with the neutralizing
f dilated, disorganized, irregularly-shaped vascular structures (arrows).
analysis of total microvascular density (G), density of uncoated vessels
ibition significantly increased microvascular density (**p  0.01 vs.
s. IgG-injected mice) (H), but decreased the density of coated vessels
R- inhibition did not affect vascular maturation. Other abbreviationsn resu
rct v
erfus
ion o
tative
 inh
.01 vDGFR- inhibition also increased macrophage density
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December 5, 2006:2315–23 PDGF Signaling in Myocardial Infarctionut did not induce hemorrhagic infiltrates in the scar. In
ontrast, neutrophil density after 7 days of reperfusion was
ow in both antibody-treated and control animals (Fig. 7E).
ISCUSSION
DGF signaling modulates fibrosis and angiogenesis.
latelet-derived growth factors are a family of disulfide-
inked dimeric proteins encoded by four genes, PDGF-A,
B, -C, and -D, that signal by binding to homodimers or
eterodimers of the 2 PDGF receptor proteins,
DGFR- and PDGFR-. The PDGF isoforms medi-
te fibrogenic actions and play an important role in
egulation of angiogenesis. PDGFR- and PDGFR-
ctivation stimulates fibroblast migration and gene ex-
ression (6); ligands of these receptors are known induc-
rs of cardiac fibrosis. Cardiac overexpression of the
DGFR- ligand PDGF-C induced fibrosis, collagen
eposition, vascular defects, and myocardial hypertrophy
22). In addition, transgenic overexpression of the active
ore domain of PDGF-D, a PDGFR- ligand, resulted
n cardiac fibrosis followed by dilated cardiomyopathy
nd subsequent cardiac failure. On the other hand,
xtensive evidence supports the crucial role of PDGFR-
–mediated interactions in recruitment of mural cells by
ewly formed vessels (23–25). Genetic disruption of
DGF-B or PDGFR- in mice results in virtually
dentical phenotypes, leading to the development of
icrovascular leakage, lethal hemorrhage, and edema in
ate embryogenesis (26,27); these defects are caused by
igure 7. Hemorrhagic foci in PDGFR- antibody-treated infarcts. (A) Af
ound with significant deposition of extracellular matrix and no red blood
PB5 resulted in extensive extravasation of red blood cells in the infarct (
PA5 did not induce hemorrhagic areas in the infarct. (D) Quantitative an
DGFR- inhibition resulted in enhanced macrophage density in the i
eutrophil density was low in the mature scar after 7 days of reperfusion, and
s in Figure 5.severe deficit in pericyte investment (12). Thus, sDGFR- signaling plays an important role in stabiliz-
ng the vasculature through acquisition of a mural coat.
DGFR- signaling critically regulates maturation of
he infarct vasculature. Our study explored for the first
ime the functional role of PDGF signaling in healing
yocardial infarcts. We showed that both PDGF receptors
xert important and distinct actions in regulation of the
ellular events associated with formation of the scar. Al-
hough both receptors mediate fibrogenic effects (Fig. 5),
DGFR- signaling also plays a unique and crucial role in
ascular maturation by regulating coating of infarct mi-
rovessels with mural cells (Fig. 6). The PDGFR- inhi-
ition through injection of the neutralizing antibody APB5
15) critically impaired vascular maturation in healing in-
arcts. The APB5 injection resulted in defective investment
f infarct microvessels with mural cells, increased capillary
ensity, and formation of tortuous and dilated vascular
tructures (Fig. 6). The role of PDGFR- signaling in
ealing infarcts likely involves a paracrine interaction be-
ween endothelial and mural cells: endothelial cells secrete
DGF-B, whereas pericytes and smooth muscle cells ex-
ress PDGFR- (28). The importance of the endothelial
ell as a source of PDGF-B is illustrated by the severe
ericyte deficiency noted in mice with endothelium-specific
blation of PDGF-B (29,30). In contrast, selective
DGF-B disruption in hematopoietic cells has no obvious
ffects on the vasculature (31).
The dilated and tortuous vasculature noted in APB5-
reated infarcts suggests an important role for PDGFR-
ays of reperfusion, immunoglobulin IgG-treated mice show a well-formed
travasation. (B) The PDGFR- inhibition with the neutralizing antibody
s). (C) In contrast, PDGFR- inhibition with the neutralizing antibody
of macrophage density in the infarcted myocardium. The PDGFR- and
ted myocardium (**p  0.01 vs. IgG-treated animals). (E) In contrast,
ignificantly different between groups (magnification 400). Abbreviationster 7 d
cell ex
arrow
alysis
nfarcignaling in regulating vessel size and shape. Hellstrom et al.
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PDGF Signaling in Myocardial Infarction December 5, 2006:2315–2313) showed that PDGFB- and PDGFR-–deficient em-
ryos show increased and variable capillary diameter with
igh- and low-diameter segments. In addition, pericyte
oating inhibits endothelial proliferation and suppresses
ngiogenesis (32). Our findings suggest that PDGFR-–
ediated mural cell recruitment may be a crucial step in
aturation of the infarct vasculature and in suppression of
he angiogenic process in the mature scar.
DGFR- signaling does not regulate vascular matura-
ion but promotes collagen deposition. In contrast,
DGFR- inhibition did not affect vascular maturation but
ignificantly decreased collagen deposition in the infarcted
yocardium (Fig. 5). This finding is consistent with the
stablished role of PDGFR- ligands (such as PDGF-AA
nd PDGF-C) in the development of myocardial fibrosis.
DGF-AA potently stimulates cardiac fibroblast prolifera-
ion inducing cell division to the same extent and with the
ame kinetics as PDGF-BB (33); PDGF-AA may also
ediate, at least in part, the fibrogenic actions of angioten-
in II in the heart (34). In addition, PDGF-C induces
broblast proliferation (35) and promotes cardiac fibrosis
hen overexpressed in transgenic mice (22).
DGFR- signaling stabilizes the infarct vasculature
romoting maturation of the scar and resolution of
nflammation. Resolution of inflammation is critical for
ffective cardiac repair after myocardial infarction. Chemo-
ine and cytokine expression is markedly but transiently
nduced in the infarcted myocardium (17); suppression of
nflammatory gene synthesis is followed by resolution of the
nflammatory infiltrate. We have recently identified
hrombospondin-1 mediated transforming growth factor-
ctivation as a crucial mechanism for suppression of the
nflammatory response (36) in healing myocardial infarcts.
hrombospondin-1 / infarcts showed increased and
rolonged inflammation and expansion of the inflammatory
rocess into the noninfarcted myocardium; this resulted in
dverse postinfarction remodeling. Thus, timely suppression
f the inflammatory response is critical for optimal repair.
ur current study identifies another important mechanism
ith a key role for resolution of inflammation. Disruption of
DGFR- signaling results in prolonged red blood cell and
onocyte/macrophage extravasation in the infarcted myo-
ardium (Fig. 7), suggesting that PDGFR-–mediated
ascular maturation is critical for resolution of the inflam-
atory process. The pro-inflammatory effects of PDGFR-
nhibition lead to formation of a more cellular wound, with
ower collagen content. In addition, inhibition of the direct
timulatory effects of PDGFR- signaling on fibroblast
igration, proliferation, and activation (37,38) may further
uppress fibrous tissue deposition in the healing infarct.
mpaired maturation of the infarct and decreased collagen
ontent may decrease tensile strength, adversely affecting
ostinfarction remodeling.
tudy limitations. Antibody neutralization is a valuable
ool for temporary inhibition of the biological effects of
DGF. However, this strategy has significant limitations.
1he exact dose of neutralizing antibody needed to inhibit a
articular biological response cannot be predicted. In addi-
ion, the delivery of the antibody to the reperfused myocar-
ium may vary among experiments. We did not quantita-
ively evaluate the effectiveness of the anti-PDGF
ntibodies in inhibition of PDGF signaling in the infarcts.
lthough these antibodies have been extensively used for in
ivo neutralization of PDGF-mediated effects (15,20,21) in
urine models, the dose we used may have resulted in
artial inhibition of PDGF signaling. In addition, our study
id not quantitatively assess PDGF-A and -B chain protein
evels in the infarcted heart and did not identify the cell
ypes expressing PDGFR- in the infarct.
onclusions. The PDGF-mediated pathways play crucial
ut distinct roles in regulating postinfarction repair. Both
DGFR- and PDGFR- signaling pathways mediate
brogenic responses, probably through direct effects on
broblasts. However, activation of the PDGF-B/
DGFR- pathway is also involved in recruitment of mural
ells by infarct neovessels, critically regulating acquisition of
mural coat by the vasculature. Coating and maturation of
he vasculature is an important step in suppression of the
ngiogenic process and promotes resolution of inflamma-
ion by preventing extravasation of blood cells into the
ature scar. Disruption of PDGFR- signaling results in
ormation of a defective infarct vasculature, impaired mat-
ration of the scar, prolonged inflammation, and decreased
ollagen content in the wound. Defective scar formation
ay adversely affect function of the infarcted heart by
nhancing left ventricular remodeling.
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